Development of a novel membrane coating technology for the formulation of orally disintegrating tablets to deliver flucloxacillin

传统上，制药行业在获得许可时一直不愿在儿童中进行临床试验。这导致了许多药物不是专门为儿童使用而设计的情况，这可能导致疗效差。为了解决这个问题，欧洲药品管理局最近发布了一份针对儿童非专利药品研究的优先清单。该项目希望通过研究和开发优先满足儿童需要的药物来实现这份清单的目标。该项目的成功成果将是开发适合儿童年龄的配方，以适当、有效和安全的方式提供药物。

Traditionally there has been a reluctance in the pharmaceutical industry to carry out clinical trials in children at the time of licensing. This has led to the scenario where many medicines are not specifically designed for use in children, which can result in poor effectiveness. To address this issue, the European Medicines Agency has recently issued a priority list for studies into non-patented medicinal products for children. This project hopes to exploit the objective of this list by undertaking research and development into medicines prioritised for need in children. The successful outcome of this project will be the development of age appropriate formulations for children, that will deliver medicines in an appropriate, efficacious and safe manner.